9 completed, 1 recruiting. 8 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Recruiting 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 1 | Completed 1 |
Follow aTyr Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) efzofitimod 450 mg, efzofitimod 270 mg, Placebo - Interstitial Lung Disease | Phase 2 | Recruiting | aTyr Pharma, Inc. | 25 | 2023-10-26 | 2025-05-07 |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo - Pulmonary Sarcoidosis | Phase 3 | Completed | aTyr Pharma, Inc. | 268 | 2022-09-15 | 2026-06-04 |
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo - SARS-CoV-2 (COVID-19) Severe Pneumonia | Phase 2 | Completed | aTyr Pharma, Inc. | 36 | 2020-06-04 | 2023-08-18 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 37 | 2019-01-29 | 2023-07-18 |
| Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) ATYR1940 - Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 8 | 2016-07-13 | 2023-12-22 |
| Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy ATYR1940 - Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 8 | 2016-03-30 | 2023-10-19 |
| Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) ATYR1940, Placebo - Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 18 | 2015-11-30 | 2023-10-19 |
| Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension ATYR1940 - Facioscapulohumeral Muscular Dystrophy | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 9 | 2015-08-13 | 2023-08-18 |
| Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy Placebo, ATYR1940 - Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 20 | 2014-09-04 | 2021-08-11 |
| A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD Facioscapulohumeral Muscular Dystrophy | Completed | Cooperative International Neuromuscular Research Group | 53 | 2012-07-01 | 2017-10-11 |
Muscular Dystrophy, Facioscapulohumeral (6) · Lung Diseases, Interstitial (3) · Fibrosis (2) · Granuloma (2) · Inflammation (2) · Lymphoproliferative Disorders (2) · Muscular Dystrophies, Limb-Girdle (2) · Pneumonia (2) · Sarcoidosis (2) · Sarcoidosis, Pulmonary (2) · COVID-19 (1) · Limb-girdle muscular dystrophy, type 2B (1) · Respiratory Distress Syndrome (1) · Scleroderma, Systemic (1)
United States (10) · Italy (5) · France (4) · Netherlands (3) · Denmark (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Germany (1) · Japan (1) · Puerto Rico (1) · Spain (1) · Sweden (1)
Lisa Carey (2) · Gennyne Walker (1) · Jean K Mah, MD, MS (1) · Sanjay Shukla, MD (1)
PMID 36356657, PMID 37854715, PMID 37902990
2014 (2), 2015 (2)